The article is a short overview of a proposal of a CubeSat type nanosatellite designed to conduct biopharmaceutical tests on the low earth orbit. Motivations behind the emerging demand for such solution nowadays and in the close future are emphasized. The possible objectives and challenges to be addressed in the planned biopharmaceutical CubeSat missions are discussed. In particular, it is hard to imagine progress of the space tourism and colonization of Moon and Mars without a wide-ranging development of pharmaceutics dedicated to be used in space. Finally, an exemplary layout of a 3U type CubeSat is presented. We underline that, thanks to recent development in both nanosatellite technologies and lab-on-a-chip type biofluidic systems, the proposed idea becomes now both feasible and relatively affordable.
Get full access to this article
View all access options for this article.
References
1.
MurphySV, AtalaA. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014; 32:773–85.
2.
DittrichPS, ManzA. Lab-on-a-chip: microfluidics in drug discovery. Nat Rev Drug Discov. 2006; 5:210–18.
EhrenfreundP, McKayC, RummelJD, et al.Toward a global space exploration program: A stepping stone approach. Adv Space Res. 2012; 49(1):2–48.
5.
MuskE. Making humans a multi-planetary species. New Space. 2017; 5(2):46–61.
6.
KittsC, HinesJ, AgasidE, et al.The GeneSat-1 microsatellite mission: A challenge in small satellite design. 20th Annual AIAA/USU Conference on Small Satellites, Logan, UT, 2006.
7.
KittsC, RonzanoK, RasayR, et al.Initial flight results from the PharmaSat biological microsatellite mission. 23th Annual AIAA/USU Conference on Small Satellites, Logan, UT, 2009.
8.
EhrenfreundP, RiccoAJ, SquiresD, et al.The O/OREOS mission—astrobiology in low Earth orbit. Acta Astronaut. 2014; 93:501–8.
NemavarkarP, ChourasiaBK, PasupathyK. Evaluation of radioprotective action of compounds using Saccharomyces cerevisiae. J Environ Pathol Toxicol Oncol Off Organ Int Soc Environ Toxicol Cancer. 2004; 23(2):145–51.
13.
VasudevNS, ReynoldsAR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17(3):471–94.
14.
RampersadSN. Multiple Applications of Alamar Blue as an Indicator of Metabolic Function and Cellular Health in Cell Viability Bioassays. Sensors. 2012; 12(9):12347–60.
KarouiaF, PeyvandK, PohorilleA. Toward biotechnology in space: High-throughput instruments for in situ biological research beyond Earth. Biotechnol Adv. 2017; 35:905–32.
17.
ZhangYS, ZhangYN, ZhangW. Cancer-on-a-chip systems at the frontier of nanomedicine. Drug Discov Today. 2017; 22(9):1392–9.
18.
TsaiHF, TrubeljaA, ShenAQ, BaoG. Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment. J R Soc Interface. 2017; 14:131.
19.
YorkeED, FuksZ, NortonL, et al.Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer. Cancer Res. 1993; 53(13):2987–93.
20.
EnderlingH, ChaplainMAJ. Mathematical modeling of tumor growth and treatment. Curr Pharm Des. 2014; 20(30):4934–40.
21.
GmunderFK, SuterRN, KiessM, et al.Mammalian cell cultivation in space. Adv Space Res. 1989; 9(11):119–27.
22.
FreedLE, PellisN, SearbyN, et al.Microgravity cultivation of cells and tissues. Gravit Space Biol Bull. 1999; 12(2):57–66.
23.
WongJ. Cells in space. Nat Med. 1997; 3(3):259.
24.
HaleW (ed.). Wings in Orbit: Scientific and Engineering Legacies of the Space Shuttle, 1971–2010, 1st ed. Washington, DC: US National Aeronautics and Space Admin, 2011.
